End of an era for erythropoiesis-stimulating agents in oncology.

导出原文传递

翻译打印收藏纠错

作者： Martin W,Schoen ^[1] ; Shamia,Hoque ^[2] ; Bartlett J,Witherspoon ^[3] ; Benjamin,Schooley ^[4] ; Oliver,Sartor ^[3] ; Y Tony,Yang ^[5] ; Paul R,Yarnold ^[6] ; Kevin B,Knopf ^[4] ; William J M,Hrushesky ^[7] ; Michael,Dickson ^[7] ; Brian J,Chen ^[4] ; Chadi,Nabhan ^[7] ; Charles L,Bennett ^[7]

作者单位： Department of Medicine, Saint Louis University School of Medicine, St. Louis, Missouri. ^[1] John Cochran Veterans Affairs Medical Center, St. Louis, Missouri. ^[2] Department of Civil and Environmental Engineering, University of South Carolina, Columbia, South Carolina. ^[3] Medical University of South Carolina, Charleston, South Carolina. ^[4] Tulane University School of Medicine, New Orleans, Louisiana. ^[5] George Washington University, Washington, District of Columbia. ^[6] The University of South Carolina College of Pharmacy, Columbia, South Carolina. ^[7] Arnold School of Public Health of the University of South Carolina, Columbia, South Carolina. ^[8]

关键词 adverse events deimplementation erythropoeitin erythropoesis-stimulating agents oncology